8篇
您的检索式：作者名="JAMESON MB"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase II study ofASA404(vadimezan,5,6-dimethylxanthenone-4-acetic acid/DMXAA)1800 mg/m2 combined with carboplatin and paclitax-el in previously untreated advanced non-small cell lung cancer显示文摘 | McKeage MJ Reck M Jameson MB | 2009 | Lung Cancer2009，65，2： | 1 |
| 2 | The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA) :current status and future opportunities 显示文摘 | Head M Jameson MB | 2010 | Expert Opinion on Investigational Drugs2010，19，2： | 1 |
| 3 | The development of the tumor vascular-disrupting agent ASA404 ( vadimezan, DMXAA) : current status and future opportunities 显示文摘 | Head M Jameson MB | 2010 | Expert Opin Investig Drugs2010，19，2： | 1 |
| 4 | Phase II study of ASA404 (vadimezan,5,6-dimethylxanthenone-4-acetic acid / DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer显示文摘 | McKeagea MJ Reck M Jameson MB | | 0，，02： | 1 |
| 5 | Phase Ⅱ study of ASA404 (vadimezan,5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2)combined with carboplaton and paclitaxel in previously untreated advanced non-small cell lung cancer显示文摘 | McKeage MJ Reck M Jameson MB | 2009 | Lung Cancer2009，65，2： | 1 |
| 6 | Clinical aspects of a phase I trial of 5,6-dimethylaxanthenone-4-acetic acid (DMXAA) , a novel antivascular agent显示文摘 | JAMESON MB THOMPSON PI BAGULEY BC | 2003 | Br J Cancer2003，88，12： | 1 |
| 7 | Phase ]I study on the addition of ASA404 ( vadimezan; 5,6-dimethylaxanthe- none-4-acetic acid/DMXAA) 1800rag/m(2) combined with ear- boplatin and paclitaxel in previously untreated advanced non- small cell lung cancer 显示文摘 | MCKEAGE MJ RECK M JAMESON MB | 2009 | Lung Cancer2009，65，2： | 1 |
| 8 | Phase Ⅱ study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA ) 1800 mg/m ( 2 ) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer显示文摘 | McKeage MJ Reck M Jameson MB | | Lung Cancer0，65，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员